GPNX
NOTIFICATION PROCESSED BY IB
18/12/2023
Voltar para busca
Dado oficial do USPTO
BRYVORA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
33
Atualização mais recente
18/12/2023
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
19/07/2022
Data de registro
02/05/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
02/05/2023
Última transação
02/05/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
25
Localização do titular
CH
Examinador
HSU, FONG
Unidade examinadora
O20
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
NOVARTIS AG
Representantes
Maury M. Tepper, III Tepper & Eyster, PLLC
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma; all of the aforementioned excluding pharmaceutical preparations for the treatment of genetic diseases and disorders and pharmaceutical preparations for use in enzyme therapy
Publicações
Histórico de despachos e eventos da marca no USPTO.
33 publicações encontradas
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
02/11/2023
IRRH
IRREGULARITY FROM IB EXAMINED BY MPU
02/11/2023
XXCR
GENERIC MADRID TRANSACTION CREATED
02/11/2023
IRFI
IRREGULARITY ON FINAL DECISION RECEIVED FROM IB
18/09/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/08/2023
FIMP
FINAL DISPOSITION PROCESSED
10/08/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
02/08/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/05/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
02/05/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
14/02/2023
PUBO
PUBLISHED FOR OPPOSITION
14/02/2023
GPNX
NOTIFICATION PROCESSED BY IB
13/02/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
25/01/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
25/01/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
25/01/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/01/2023
ATRV
ATTORNEY REVIEW COMPLETED
10/01/2023
CREV
CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED
10/01/2023
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
08/01/2023
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
26/11/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
26/10/2022
CNRT
NON-FINAL ACTION WRITTEN
25/10/2022
DOCK
ASSIGNED TO EXAMINER
17/10/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
01/10/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/10/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
01/10/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/10/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/10/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
01/10/2022
MAFR
APPLICATION FILING RECEIPT MAILED
20/08/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
16/08/2022
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
12/08/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BRYVORA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.